Scarica l'app Stockscreener
33.95
3.58%
-1.26
Dopo l'orario di chiusura:
33.96
0.010
+0.03%
Edgewise Therapeutics Inc Borsa (EWTX) Ultime notizie
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM) - PR Newswire
(EWTX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Number of shareholders of Edgewise Therapeutics, Inc. – NASDAQ:EWTX - TradingView
Edgewise Therapeutics, Inc. 2026 Annual Meeting Results and SEC Filing Details - Minichart
Edgewise Therapeutics Shareholders Back Board and Governance - TipRanks
Edgewise Therapeutics (EWTX) shareholders approve directors, KPMG and executive pay - Stock Titan
Edgewise: 'Buy' On Muscular Dystrophy Program Sale And EDG-7500 Advancement - Seeking Alpha
Paradigm Biocapital Advisors LP's Edgewise Therapeutics Inc(EWTX) Holding History - GuruFocus
Liquidity Mapping Around (EWTX) Price Events - Stock Traders Daily
Edgewise Therapeutics Reports Inducement Grants As Permitted By Nasdaq Listing Rules - TradingView
Edgewise Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules - 富途牛牛
Guggenheim Reaffirms Their Buy Rating on Edgewise Therapeutics (EWTX) - The Globe and Mail
Servier to Acquire Edgewise's Muscular Dystrophy Drug in USD 2.65 Billion Deal - Medical Dialogues
New Edgewise hires get 74,000 stock options as hiring inducement - Stock Titan
Edgewise sells sevasemten for up to $2.65 billion - The Pharma Letter
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal - The Globe and Mail
Assessing Edgewise Therapeutics (EWTX) Valuation After A Sharp Recent Share Price Move - Yahoo Finance
EWTX Maintained by HC Wainwright & Co. -- Price Target Raised to $45 - GuruFocus
EWTX Maintained by Wedbush -- Price Target Raised to $52.00 - GuruFocus
RBC Capital lowers Edgewise Therapeutics stock price target on deal By Investing.com - Investing.com Australia
RBC Capital lowers Edgewise Therapeutics stock price target on deal - Investing.com
RBC Lowers Price Target on Edgewise Therapeutics to $48 From $50, Keeps Outperform, Speculative Risk - marketscreener.com
Wedbush raises Edgewise Therapeutics stock price target on Servier deal - Investing.com UK
Wedbush raises Edgewise Therapeutics stock price target on Servier deal By Investing.com - Investing.com India
Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn - Yahoo Finance
Edgewise Therapeutics, IBM, Rubrik - TradingView
Servier Moves Into Muscular Dystrophy, Paying $1.5B for Assets From Edgewise Therapeutics - MedCity News
Edgewise Therapeutics (EWTX) Surges 17.5% on Market Activity - GuruFocus
How Edgewise Sweetened Its Coffers By $1.55 Billion, And Removed A Key Overhang - Investor's Business Daily
Servier to Acquire Edgewise Therapeutics (EWTX) for $2.65 Billio - GuruFocus
Raymond James raises Edgewise Therapeutics price target on Servier deal By Investing.com - Investing.com Canada
Edgewise Therapeutics stock hits all-time high of 40.6 USD By Investing.com - Investing.com South Africa
Servier Pharmaceuticals LLC and LES LABORATOIRES SERVIER, SAS entered into an Asset Purchase Agreement to acquire Sevasemten and Muscular Dystrophy Business of Edgewise Therapeutics, Inc. for $2.7 billion.. - marketscreener.com
Edgewise sells muscular dystrophy assets to Servier for $2.65B - BioWorld News
Servier buys into muscular dystrophy with potentially $2.7B deal - BioPharma Dive
Edgewise Therapeutics Shares Surge 15% to $39.40 on Promising Muscle Disease Treatment Data - International Business Times Australia
Why is Edgewise Therapeutics stock surging today? By Investing.com - Investing.com Canada
EWTX Stock Hits Record High – Why Servier Is Shelling Out $2.65B For Edgewise’s Muscular Dystrophy Business - Yahoo Finance
Servier Agrees to Acquire Muscular Dystrophy Business of Edgewise Therapeutics - Contract Pharma
Servier buys Edgewise muscular dystrophy business for up to US$2.65bn - European Biotechnology Magazine
Edgewise Therapeutics Sells Sevasemten, Refocuses on Cardiology - TipRanks
Edgewise Therapeutics stock hits all-time high of 40.6 USD - Investing.com
Edgewise Therapeutics Sells Sevasemten for Up to $2.65 Billion, Refocuses on Cardiovascular Pipeline - Minichart
Servier projette d'acquérir l'activité dystrophie musculaire d'Edgewise Therapeutics - PR Newswire
Edgewise sells muscular dystrophy unit to Servier for $2.65B By Investing.com - Investing.com Australia
Servier to acquire Edgewise muscular dystrophy unit for $2.65b By Investing.com - Investing.com South Africa
France: Servier acquires muscular dystrophy business of Edgewise Therapeutics for up to US$2.65bn - Investors in Healthcare
Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business - The Manila Times
Edgewise sells muscular dystrophy unit to Servier for $2.65B - Investing.com
Edgewise Therapeutics (EWTX) to sell sevasemten business to Servier for up to $2.65B - Stock Titan
Edgewise's Muscular Dystrophy Business to be Acquired by Servier for Up to $2.65 Billion - marketscreener.com
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):